c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors

Francesca Miselli, Paola Casieri, Tiziana Negri, Marta Orsenigo, M. Stefania Lagonigro, Alessandro Gronchi, Marco Fiore, Paolo G. Casali, Rossella Bertulli, Antonino Carbone, Marco A. Pierotti, Elena Tamborini, Silvana Pilotti

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Purpose: To correlate morphologic changes with molecular, biochemical, and cytogenetic profiles in gastrointestinal stromal tumor (GIST) patients before and after imatinib treatment. Experimental Design: We investigated 132 tumor samples obtained from 35 patients with advanced disease who underwent resective surgery after imatinib treatment according to the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group protocol. On the basis of imaging findings, 27 patients were responders and 8 progressors, and retaining this radiological subdivision, we analyzed posttreatment morphologic changes correlating them with molecular, biochemical, and cytogenetic analyses. Results: On the basis of morphology (residual viable cellularity/proliferation markers), three subgroups were identified showing high, moderate, or low response. All of the progressing cases clustered in the low-response subgroup, whereas the responding cases were distributed in all three subgroups. The correlation between morphology and the molecular findings showed that secondary mutations segregated with the low-response subgroup, whereas c-Kit primary resistance mutations were randomly distributed in the three subgroups. Fluorescence in situ hybridization analysis of c-Kit/PDGFRA genes showed that all of the progressing cases were disomic. Referring to morphology, among the responding cases, a disomic pattern was mainly restricted to the high responders, whereas the moderate and low responders were aneusomic. Comparison of post-imatinib genomic profiles with the 23 available primary tumors showed that 17 cases carried the same cytogenetic pattern. Overall, 12 of the 27 primary tumors presented a gain/loss of c-Kit/ PDGFRA gene copy number. Conclusions: Our findings show that c-Kit/PDGFRA genomic alterations were present at disease onset in 1/3 of the examined cases. They therefore represent an early event possibly related to primary imatinib resistance in GISTs.

Original languageEnglish
Pages (from-to)2369-2377
Number of pages9
JournalClinical Cancer Research
Volume13
Issue number8
DOIs
Publication statusPublished - Apr 15 2007

Fingerprint

Gastrointestinal Stromal Tumors
Cytogenetics
Genes
Neoplasms
Mutation
Gene Dosage
Cytogenetic Analysis
Fluorescence In Situ Hybridization
Sarcoma
Research Design
Therapeutics
Imatinib Mesylate
Research

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors. / Miselli, Francesca; Casieri, Paola; Negri, Tiziana; Orsenigo, Marta; Lagonigro, M. Stefania; Gronchi, Alessandro; Fiore, Marco; Casali, Paolo G.; Bertulli, Rossella; Carbone, Antonino; Pierotti, Marco A.; Tamborini, Elena; Pilotti, Silvana.

In: Clinical Cancer Research, Vol. 13, No. 8, 15.04.2007, p. 2369-2377.

Research output: Contribution to journalArticle

Miselli, Francesca ; Casieri, Paola ; Negri, Tiziana ; Orsenigo, Marta ; Lagonigro, M. Stefania ; Gronchi, Alessandro ; Fiore, Marco ; Casali, Paolo G. ; Bertulli, Rossella ; Carbone, Antonino ; Pierotti, Marco A. ; Tamborini, Elena ; Pilotti, Silvana. / c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors. In: Clinical Cancer Research. 2007 ; Vol. 13, No. 8. pp. 2369-2377.
@article{dc1daaf975c64964b56eeefbca762f3b,
title = "c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors",
abstract = "Purpose: To correlate morphologic changes with molecular, biochemical, and cytogenetic profiles in gastrointestinal stromal tumor (GIST) patients before and after imatinib treatment. Experimental Design: We investigated 132 tumor samples obtained from 35 patients with advanced disease who underwent resective surgery after imatinib treatment according to the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group protocol. On the basis of imaging findings, 27 patients were responders and 8 progressors, and retaining this radiological subdivision, we analyzed posttreatment morphologic changes correlating them with molecular, biochemical, and cytogenetic analyses. Results: On the basis of morphology (residual viable cellularity/proliferation markers), three subgroups were identified showing high, moderate, or low response. All of the progressing cases clustered in the low-response subgroup, whereas the responding cases were distributed in all three subgroups. The correlation between morphology and the molecular findings showed that secondary mutations segregated with the low-response subgroup, whereas c-Kit primary resistance mutations were randomly distributed in the three subgroups. Fluorescence in situ hybridization analysis of c-Kit/PDGFRA genes showed that all of the progressing cases were disomic. Referring to morphology, among the responding cases, a disomic pattern was mainly restricted to the high responders, whereas the moderate and low responders were aneusomic. Comparison of post-imatinib genomic profiles with the 23 available primary tumors showed that 17 cases carried the same cytogenetic pattern. Overall, 12 of the 27 primary tumors presented a gain/loss of c-Kit/ PDGFRA gene copy number. Conclusions: Our findings show that c-Kit/PDGFRA genomic alterations were present at disease onset in 1/3 of the examined cases. They therefore represent an early event possibly related to primary imatinib resistance in GISTs.",
author = "Francesca Miselli and Paola Casieri and Tiziana Negri and Marta Orsenigo and Lagonigro, {M. Stefania} and Alessandro Gronchi and Marco Fiore and Casali, {Paolo G.} and Rossella Bertulli and Antonino Carbone and Pierotti, {Marco A.} and Elena Tamborini and Silvana Pilotti",
year = "2007",
month = "4",
day = "15",
doi = "10.1158/1078-0432.CCR-06-1745",
language = "English",
volume = "13",
pages = "2369--2377",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors

AU - Miselli, Francesca

AU - Casieri, Paola

AU - Negri, Tiziana

AU - Orsenigo, Marta

AU - Lagonigro, M. Stefania

AU - Gronchi, Alessandro

AU - Fiore, Marco

AU - Casali, Paolo G.

AU - Bertulli, Rossella

AU - Carbone, Antonino

AU - Pierotti, Marco A.

AU - Tamborini, Elena

AU - Pilotti, Silvana

PY - 2007/4/15

Y1 - 2007/4/15

N2 - Purpose: To correlate morphologic changes with molecular, biochemical, and cytogenetic profiles in gastrointestinal stromal tumor (GIST) patients before and after imatinib treatment. Experimental Design: We investigated 132 tumor samples obtained from 35 patients with advanced disease who underwent resective surgery after imatinib treatment according to the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group protocol. On the basis of imaging findings, 27 patients were responders and 8 progressors, and retaining this radiological subdivision, we analyzed posttreatment morphologic changes correlating them with molecular, biochemical, and cytogenetic analyses. Results: On the basis of morphology (residual viable cellularity/proliferation markers), three subgroups were identified showing high, moderate, or low response. All of the progressing cases clustered in the low-response subgroup, whereas the responding cases were distributed in all three subgroups. The correlation between morphology and the molecular findings showed that secondary mutations segregated with the low-response subgroup, whereas c-Kit primary resistance mutations were randomly distributed in the three subgroups. Fluorescence in situ hybridization analysis of c-Kit/PDGFRA genes showed that all of the progressing cases were disomic. Referring to morphology, among the responding cases, a disomic pattern was mainly restricted to the high responders, whereas the moderate and low responders were aneusomic. Comparison of post-imatinib genomic profiles with the 23 available primary tumors showed that 17 cases carried the same cytogenetic pattern. Overall, 12 of the 27 primary tumors presented a gain/loss of c-Kit/ PDGFRA gene copy number. Conclusions: Our findings show that c-Kit/PDGFRA genomic alterations were present at disease onset in 1/3 of the examined cases. They therefore represent an early event possibly related to primary imatinib resistance in GISTs.

AB - Purpose: To correlate morphologic changes with molecular, biochemical, and cytogenetic profiles in gastrointestinal stromal tumor (GIST) patients before and after imatinib treatment. Experimental Design: We investigated 132 tumor samples obtained from 35 patients with advanced disease who underwent resective surgery after imatinib treatment according to the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group protocol. On the basis of imaging findings, 27 patients were responders and 8 progressors, and retaining this radiological subdivision, we analyzed posttreatment morphologic changes correlating them with molecular, biochemical, and cytogenetic analyses. Results: On the basis of morphology (residual viable cellularity/proliferation markers), three subgroups were identified showing high, moderate, or low response. All of the progressing cases clustered in the low-response subgroup, whereas the responding cases were distributed in all three subgroups. The correlation between morphology and the molecular findings showed that secondary mutations segregated with the low-response subgroup, whereas c-Kit primary resistance mutations were randomly distributed in the three subgroups. Fluorescence in situ hybridization analysis of c-Kit/PDGFRA genes showed that all of the progressing cases were disomic. Referring to morphology, among the responding cases, a disomic pattern was mainly restricted to the high responders, whereas the moderate and low responders were aneusomic. Comparison of post-imatinib genomic profiles with the 23 available primary tumors showed that 17 cases carried the same cytogenetic pattern. Overall, 12 of the 27 primary tumors presented a gain/loss of c-Kit/ PDGFRA gene copy number. Conclusions: Our findings show that c-Kit/PDGFRA genomic alterations were present at disease onset in 1/3 of the examined cases. They therefore represent an early event possibly related to primary imatinib resistance in GISTs.

UR - http://www.scopus.com/inward/record.url?scp=34247855989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247855989&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-06-1745

DO - 10.1158/1078-0432.CCR-06-1745

M3 - Article

C2 - 17438095

AN - SCOPUS:34247855989

VL - 13

SP - 2369

EP - 2377

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 8

ER -